TLX252-Tx (225Ac-DOTA-girentuximab): Telix has received approval in Australia to commence ALPHIX, a Phase 1, FIH study of its targeted alpha therapy candidate for advanced metastatic kidney cancer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback